Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mary Spellman, MD
Vyne Therapeutics Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
52 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Study Site 332
Anniston, Alabama, United States
- Study Site 363
Birmingham, Alabama, United States
- Study Site 340
Hoover, Alabama, United States
- Study Site 364
Glendale, Arizona, United States
- Study Site 334
Cerritos, California, United States
- Study Site 386
Encinitas, California, United States
- Study Site 366
Fountain Valley, California, United States
- Study Site 338
Los Angeles, California, United States
- Study Site 383
North Hollywood, California, United States
- Study Site 374
Oceanside, California, United States
- Study Site 347
San Diego, California, United States
- Study Site 356
San Diego, California, United States
- Study Site 333
San Francisco, California, United States
- Study Site 376
Santa Monica, California, United States
- Study Site 358
Denver, Colorado, United States
- Study Site 370
Jacksonville, Florida, United States
- Study Site 331
Miami, Florida, United States
- Study Site 348
Miami, Florida, United States
- Study Site 378
Miami, Florida, United States
- Study Site 353
Pinellas Park, Florida, United States
- Study Site 368
Tampa, Florida, United States
- Study Site 377
Tampa, Florida, United States
- Study Site 369
Atlanta, Georgia, United States
- Study Site 349
Savannah, Georgia, United States
- Study Site 381
Chicago, Illinois, United States
- Study Site 360
New Albany, Indiana, United States
- Study Site 380
Bardstown, Kentucky, United States
- Study Site 344
Louisville, Kentucky, United States
- Study Site 379
Boston, Massachusetts, United States
- Study Site 350
Warren, Michigan, United States
- Study Site 371
Saint Joseph, Missouri, United States
- Study Site 387
Las Vegas, Nevada, United States
- Study Site 352
Berlin, New Jersey, United States
- Study Site 375
Forest Hills, New York, United States
- Study Site 373
Rochester, New York, United States
- Study Site 341
High Point, North Carolina, United States
- Study Site 355
Shelby, North Carolina, United States
- Study Site 337
Oklahoma City, Oklahoma, United States
- Study Site 345
Johnston, Rhode Island, United States
- Study Site 362
Providence, Rhode Island, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2016
- Primary completion
- 16 Jan 2018
- Completion
- 23 Feb 2018
- Last update posted
- 20 May 2021
- Registered enrollment
- 484
- Registry id
- NCT02975206
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.